Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.58 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | ATF4 | P18848 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101043 | 1.00 | CHRNA7 (0.58) | CHRNA7CNR1PRKAA2ATF4HTR7 | |
| SCHEMBL6101652 | 0.94 | CHRNA7 (0.50) | CHRNA7CNR1PRKAA2ATF4HTR7 | |
| SCHEMBL6098653 | 0.87 | CHRNA7 (0.59) | CHRNA7CNR1PRKAA2HTR7HSD11B1 | |
| SCHEMBL6635518 | 0.87 | CHRNA7 (0.59) | CHRNA7CNR1PRKAA2HTR7HSD11B1 | |
| SCHEMBL6098659 | 0.87 | CHRNA7 (0.59) | CHRNA7CNR1PRKAA2HTR7HSD11B1 | |
| SCHEMBL6100835 | 0.86 | CHRNA7 (0.61) | CHRNA7CNR1PRKAA2ATF4HSD11B1 | |
| SCHEMBL6100828 | 0.86 | CHRNA7 (0.61) | CHRNA7CNR1PRKAA2ATF4HSD11B1 | |
| SCHEMBL6100201 | 0.85 | CHRNA7 (0.55) | CHRNA7CNR1PRKAA2 | |
| SCHEMBL6100212 | 0.85 | CHRNA7 (0.55) | CHRNA7CNR1PRKAA2 | |
| SCHEMBL6632916 | 0.85 | CHRNA7 (0.55) | CHRNA7CNR1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | claimed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | CHRNA7 1836/4885CNR1 343/4885PRKAA2 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.